TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9638313
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) at a daily dose of 1,200 mg for 4 weeks
Study: 8304303
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for 1 wk plus omeprazole for 4 wk (Triple+OMP)
Study: 3054251
Drug: Hydroxypropylmethylcellulose (HPMC)
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropylmethylcellulose (HPMC) 2% solution
Study: 31058716
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg daily)
Study: 31058716
Drug: Granisetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (2 mg daily)
Study: 23390069
Drug: Intralesional antimony
Normalized name: antimony
DrugBank: Antimony (DB13110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional antimony (IL Sb) 650 µg/mm² on days 1, 3, and 5
Study: 23390069
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream daily for 20 days
Study: 20920142
Drug: SFC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC plus Tio (50/250 µg twice daily plus 18 µg once daily)
Study: 20920142
Drug: Tio alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tio alone (18 µg once daily)
Study: 19686407
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg, 4 mg/h infusion
Study: 19686407
Drug: pantoprazole 80
Normalized name: pantoprazole 80 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 80 mg bolus followed by 8 mg/h
Study: 19686407
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg bolus injection every 24 h
Study: 19686407
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori (−) group with continuous infusion
Study: 19686407
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori (+) group with continuous infusion
Study: 8246275
Drug: Clomipramine 50
Normalized name: clomiPRAMINE 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 50 mg
Study: 27084959
Drug: VX-509 100
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-509 100 mg
Study: 27084959
Drug: VX-509 200
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-509 200 mg
Study: 27084959
Drug: VX-509 300
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-509 300 mg
Study: 27084959
Drug: VX-509 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-509 (all doses)
Study: 24952856
Drug: Acarbose, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose, an α‐glucosidase inhibitor that lowers postprandial blood glucose
Study: 20378636
Drug: Immediate testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate testing and treatment for chlamydial infection
Study: 12538422
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg subcutaneously twice daily)
Study: 12538422
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (70-U/kg bolus; 15 U x kg(‐1) x h(‐1) infusion for 48 hours)
Study: 8559201
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles
Study: 6194568
Drug: Nasogastric suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasogastric suction and intravenously administered fluids (SD)
Study: 6194568
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of clear fluids (FF)
Study: 27520087
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone and hydroxypropyl methylcellulose (treatment group)
Study: 27520087
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone (control group)
Study: 19245362
Drug: Enteral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral iron supplementation (ferrous sulfate 325 mg three times daily)
Study: 15133003
Drug: Insulin-resistant group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant group (IR)
Study: 15133003
Drug: Insulin-sensitive group
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive group (IS)
Study: 2576360
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 10 mg picumast dihydrochloride
Study: 2576360
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 10 mg picumast dihydrochloride
Study: 29672965
Drug: 103-mg p-synephrine
Normalized name: synephrine
DrugBank: Synephrine (DB09203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 103-mg p-synephrine (S)
Study: 29672965
Drug: Caffeine +
Normalized name: Voost Energy Caffeine + B Vitamin Complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine + 104-mg p-synephrine
Study: 29672965
Drug: 240-mg caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240-mg caffeine
Study: 29672965
Drug: 337-mg caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 337-mg caffeine + 46-mg p-synephrine
Study: 29672965
Drug: 325-mg caffeine
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325-mg caffeine
Study: 24461464
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl and ketorolac infusion on demand by patient‐controlled analgesia (IV PCA group, n=31)
Study: 21883496
Drug: Zearalenone (ZEA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zearalenone (ZEA) at 2 mg/kg
Study: 21883496
Drug: Isoflavone (ISO)
Normalized name: iso-sulfan blue
DrugBank: Isoflavone (DB12007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone (ISO) at 600 mg/kg
Study: 19488681
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (1,830 mg/day) for 30 days
Study: 17335689
Drug: Growth factors
Normalized name: INVEST HEMATOLOGIC DEFICIENCIES,HEMATOPOEITIC GROWTH FACTORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth factors as chemotherapy-sensitizing agents
Study: 17335689
Drug: Growth factor
Normalized name: Growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth factor monotherapy
Study: 17335689
Drug: Growth factors
Normalized name: INVEST HEMATOLOGIC DEFICIENCIES,HEMATOPOEITIC GROWTH FACTORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth factors administration
Study: 12781094
Drug: AAS (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAS (100 mg/day) on awakening
Study: 12781094
Drug: AAS (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAS (100 mg/day) before bedtime
Study: 10682031
Drug: Aerosolized tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aerosolized tobramycin (6 mg/kg/day, n = 21)
Study: 9100167
Drug: Dexamethasone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15 mg/kg, intravenously, once on admission), colchicine (0.5 mg, orally, daily, for 3 days), pentoxifylline (400 mg, orally, daily, for 3 days)
Study: 8402761
Drug: Triflusal (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (300 mg t.i.d.; n = 143)
Study: 3781678
Drug: Standard dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose: CHL 25 mg and MET 200 mg
Study: 3781678
Drug: Lower dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose: CHL 12.5 mg and MET 100 mg
Study: 3781678
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (standard dose) vs Lower dose
Study: 27749603
Drug: Darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (800/100 mg once daily) with Raltegravir (400 mg twice daily, Arm1)
Study: 27749603
Drug: Darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (800/100 mg once daily) with Tenofovir/Emtricitabine (245/200 mg once daily, Arm2)
Study: 20096545
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester (staest) spread (2 g/day) for four weeks
Study: 20096545
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol ester (steest) spread (2 g/day) for four weeks
Study: 17326149
Drug: Isoleucine infusion
Normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoleucine infusion
Study: 10984298
Drug: Somatropin treatment
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Somatropin treatment (rhGH, 12 microg/kg/day) for 6 months
Study: 3310721
Drug: Glycopyrronium 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium 0.005 mg/kg
Study: 31852410
Drug: Intraarterial thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial thrombolysis (recombinant tissue plasminogen activator, 0.5 mg/ml, maximum dose limit 22.5 mg)
Study: 30481596
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone prophylaxis (group B)
Study: 25294647
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells (BMMCs)
Study: 20032546
Drug: PEG‐IFN‐alpha2a 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐alpha2a 180 microg/week plus ADV 10 mg/day
Study: 20032546
Drug: PEG‐IFN‐alpha2a monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐alpha2a monotherapy
Study: 14973216
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg per day)
Study: 11281392
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (Pnc PS)
Study: 9677439
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose IL-2/IFN-alpha combination therapy (protocol 1)
Study: 9677439
Drug: Low dose,
Normalized name: Aspirin Low Dose, 81 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose, long-term continuous IFN-alpha/IL-2 administration (protocol 2)
Study: 9677439
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose IFN-alpha and 13-cis-retinoic acid therapy in repetitive weekly cycles (protocol 3)
Study: 7988246
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution placebo control
Study: 2735177
Drug: 0.025 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg/kg ATR
Study: 2735177
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg DTC
Study: 29567335
Drug: Family nursing
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family nursing therapeutic conversations (FNTC) as a supplement to usual care
Study: 26664396
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/day) plus Risperidone (6 mg/day)
Study: 26664396
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Risperidone (6 mg/day)
Study: 23144046
Drug: Insulin-glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-glucose infusion during the first 48 hours of hospitalization for AMI
Study: 19663190
Drug: Combined basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined basic treatment with methotrexate (7.5 mg/week) and plaquenil (0.2 mg/day)
Study: 15239097
Drug: Clevudine 10
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 10 mg
Study: 15239097
Drug: Clevudine 50
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 50 mg
Study: 15239097
Drug: Clevudine 100
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 100 mg
Study: 15239097
Drug: Clevudine 200
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 200 mg
Study: 15239097
Drug: Clevudine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine (all doses)
Study: 9205761
Drug: Ebrotidine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 800 mg and Cimetidine 800 mg
Study: 1770193
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) after postoperative day 5.
Study: 1770193
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN).
Study: 7066138
Drug: Extradural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural pethidine 25 mg with adrenaline 25 micrograms
Study: 7066138
Drug: Extradural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural pethidine 25 mg without adrenaline
Study: 30462220
Drug: Study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug interrupted ≤3 days
Study: 30462220
Drug: Study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug interrupted >3 days
Study: 27068695
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg oral doses)
Study: 21069585
Drug: Telephone-administered supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered supportive emotion-focused therapy (T-SEFT)
Study: 11269767
Drug: Topical allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical allergen challenge
Study: 8310985
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil with 1 g squalene for 9 weeks
Study: 8310985
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g squalene/d for 6 weeks
Study: 3396238
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (Mg) therapy for 48 hours
Study: 26554630
Drug: Tapentadol PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol PR 50 mg (titrated to maximum 250 mg)
Study: 26554630
Drug: Oxycodone/naloxone PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/naloxone PR 10 mg/5 mg (titrated to maximum 40 mg/20 mg plus oxycodone PR 10 mg)
Study: 21940331
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of metoclopramide (15 minutes before swallowing CE)
Study: 21940331
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of metoclopramide
Study: 18332401
Drug: Psyllium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium supplementation at 7 or 14 g/d for 3 months
Study: 16520350
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (50 mg i.v. once weekly)
Study: 14605047
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 800 microg/d for 2 weeks
Study: 14605047
Drug: High-dose ICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ICS (group B)
Study: 14605047
Drug: High-dose FP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FP (group A)
Study: 10883990
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.25 % bupivacaine instilled into the gallbladder bed and Calot's triangle area
Study: 8883017
Drug: A1(OH)3 1
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1(OH)3 1 tablet 3 times per day (about 302 mg/day of elemental A1) for 3 months
Study: 8140182
Drug: Fluvoxamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine and exposure therapy (group Fe)
Study: 8140182
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy with placebo (group Pe)
Study: 8140182
Drug: Antiexposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiexposure therapy with fluvoxamine (group F)
Study: 26485620
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening (5 annual scans)
Study: 23106107
Drug: Secukinumab 3
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 3 × 150 mg
Study: 23106107
Drug: Secukinumab 3
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 3 × 75 mg
Study: 21967800
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (medical device without active principles)
Study: 16371228
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management of the third stage of labor with 600 mcg of oral misoprostol
Study: 14616378
Drug: 5% alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% alpha-lipoic acid cream
Study: 31321071
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day fluoxetine for 60 days
Study: 27368881
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg daily; 3 weeks on/1 week off) with fulvestrant (500 mg intramuscular injection)
Study: 27368881
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with fulvestrant (500 mg intramuscular injection)
Study: 25191661
Drug: 0.5mg/kg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg/kg oral midazolam premedication
Study: 20082603
Drug: Veralipride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralipride (100 mg/day)
Study: 15960574
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day of conjugated estrogen
Study: 7669311
Drug: Guanfacine 1
Normalized name: guanfacine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 1 mg
Study: 23836811
Drug: Adjustment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment group (6 group treatment sessions)
Study: 16360972
Drug: CIFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIFN plus ribavirin (induction-dosing)
Study: 9494772
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg norethisterone
Study: 9494772
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg norethisterone acetate
Study: 9494772
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg norethisterone acetate
Study: 7692687
Drug: 3-week therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week therapy series of ultrasound (6 times a week)
Study: 7692687
Drug: 6-week therapy
Normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-week therapy series of ultrasound (3 times a week)
Study: 7692687
Drug: 9-week therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-week therapy series of ultrasound (2 times a week)
Study: 26823602
Drug: First-line bevacizumab-based
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First-line bevacizumab-based therapy
Study: 22496207
Drug: Sulfasalazine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (4 days treatment, n = 5)
Study: 22496207
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no treatment, n = 5)
Study: 22496207
Drug: Sulfasalazine (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (long-term treatment)
Study: 2989349
Drug: Placebo (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (long-term treatment)
Study: 19085342
Drug: Candesartan-HCT 32/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan-HCT 32/12.5 mg
Study: 19085342
Drug: Candesartan-HCT 32/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan-HCT 32/25 mg
Study: 10357049
Drug: Teicoplanin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (400 mg)
Study: 8733702
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol for mucositis prophylaxis
Study: 1656517
Drug: 2.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/day omega-3-PUFA
Study: 1656517
Drug: 4.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g/day omega-3-PUFA
Study: 31490536
Drug: Clopidogrel bisulphate
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel bisulphate plus aspirin (600 mg on day 1, then 75 mg per day through day 90; plus 50 to 325 mg of aspirin per day)
Study: 31490536
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin (same range of dosages as clopidogrel)
Study: 31490536
Drug: Clopidogrel bisulphate
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel bisulphate plus aspirin